Pluristem Therapeutics, Inc. (NASDAQ:PSTI)

CAPS Rating: 1 out of 5

Results 1 - 11 of 11

Recs

0
Member Avatar pchop12316 (37.84) Submitted: 1/29/2015 11:24:32 AM : Underperform Start Price: $3.68 PSTI Score: -1.01

talk is cheap

Recs

2
Member Avatar zzlangerhans (99.85) Submitted: 1/28/2015 10:11:53 PM : Underperform Start Price: $3.36 PSTI Score: -12.17

Pluristem is a stem cell soup peddler that likes to talk loud and do little. In the four years I've been following them, they've completed one clinical trial and they've done nothing to follow up on their claims of success. They claimed for years to be on the verge of initiating a phase II/III trial of PLX cells for critical limb ischemia but never did so. They also claimed that PLX cells were responsible for engraftment of bone marrow transplants that saved the lives of three patients with aplastic anemia, but failed to update the world when two of those patients died shortly afterwards. Likewise, they have never followed up on their supposed amazing success in this compassionate use protocol with a clinical trial. As of now, only two early stage trials of PLX are in progress with no clear guidance for when they will be completed.

Today Pluristem stock was up as much as 25% because a press release distribution service called Marketwired announced that a stock market research firm named Acceleron Equity Research had issued an updated coverage report on the company, and conveniently provided a link to this very positively spun report. Well, who or what is Acceleron Equity Research and why should we listen to their opinion? Good question and good luck finding an answer. Acceleron's website is now a little more developed than it was in October when I first encountered them shilling for a doomed scam called Cel-Sci. At that time the supposed links for their research reports went to pages filled with Latin-sounding nonsense. As of now, Acceleron only has public opinions on Cel-Sci, Oramed, and Pluristem all of which are seriously questionable in terms of legitimacy. Acceleron also has testimonials from Steven, John, Andrew, and Kathy. Kathy, a retail investor, says "In your coverage about Flux Power Holdings your research report warned investors about a real risk that product development takes longer than expected in green energy product development and there might may be delayed getting the firm's product to market. That fear was realized, it seems." Acceleron's website contains no mentions of or links to any reports about Flux Power Holdings. However, a Google search indicates that in November 2012 Acceleron initiated coverage of Flux Power Holdings with a Buy rating and a twelve month price target of $5.80. In November 2012 that stock traded at 1.7. And now? 0.07. The stock plunged to a dime in the seven months after Acceleron recommended it, but now they're claiming that they actually warned against it. Here's the link to the article

http://www.reuters.com/article/2012/11/30/idUS146402+30-Nov-2012+HUG20121130

Don't bother clicking on the link to the PDF of the report itself. That link takes you to the stub for acceleronequity.com, a URL which is apparently on sale for $3599. Acceleron Equity Research now lives at acceleronequity.net.

Steven states he is happy with Acceleron because "When Tekmira Pharmaceuticals shares were trading at only $4.50, Acceleron researchers said the developer of RNA interference therapeutics was to be come a leader in the sector. I paid attention and listened to all of your updates along the way to $28.00 per share.". There is no current mention of Tekmira on the Acceleron website and a Google search for Acceleron Equity Research and Tekmira yields no evidence of any report or recommendation.

Meanwhile, Andrew says "In laste (sic) 2013, Acceleron stated in its initiation report that Blue Sphere was significantly undervalued and initiated Blue Sphere with a BUY rating. That was a great call. Thank you!"

Acceleron did initiate coverage of Blue Sphere in December 2013 when the share price was 0.00168 just before a 113:1 reverse split, with a twelve month target of 0.02. That's a twelve month price target of two cents. The share price immediately rose more than 100% to 0.00425 but that was as high as it got. With four months it was down to 70% below the price at which Acceleron initially recommended them. What do we call a firm that issues buy recommendations and price targets on OTC stocks that trade for a fraction of a penny? That's right, a bucket shop! "Andrew" must have ten kinds of brain damage to call the Blue Sphere recommendation a great call, unless he bought before Acceleron's recommendation and sold the day of the pump.

So now we know that Acceleron is a lame ass bucket shop that lies about its track record in phony testimonials. Who is behind Acceleron? Acceleron's website won't tell you, but the Marketwired press release for Pluristem does. The contact is listed as M. Morhamus. Who is M. Morhamus? Could it be this guy? http://seekingalpha.com/author/michael-morhamus

Which biopharmas has Michael Morhamus flogged on Seeking Alpha? A motley crew of scams and doomed stocks including Cel-Sci (of course), Ampio, ImmunoCellular, NeoStem, and Zalicus. He has also been a frequent contributor to M.E. Garza's scam rag BioMedReports.

So now we know what Acceleron is. Yet another head of the Hydra I call the Axis of Evil that pops up in various forms to sell stocks like Pluristem, NeoStem, Cleveland BioLabs, Immunocellular, and Ampio to naive retail traders. It's a sorry commentary on the mentality of traders in these stocks that a pathetic PR like the one today can induce buying in a bioturd like Pluristem. I'm short 2000 shares today at 3.42 and may upsize depending on how the stock behaves in the coming days.

Recs

0
Member Avatar SnarkyApple (54.45) Submitted: 9/13/2012 11:41:00 PM : Underperform Start Price: $3.90 PSTI Score: +40.41

Shenanigans.

Recs

0
Member Avatar shaito (< 20) Submitted: 8/20/2012 1:07:19 AM : Outperform Start Price: $3.98 PSTI Score: -47.01

the stock its in her lower price and other company with the same prodact without any life saver like psti the stoock need to be like 7-8 dollars

Recs

0
Member Avatar dolpho2 (< 20) Submitted: 8/17/2012 4:06:30 PM : Outperform Start Price: $3.98 PSTI Score: -47.01

Their technology seems to work. PLX-PAD is the only drug that heals the heart muscle instead of just prolonging life. Their drug for aplastic anaemia has been given to two people in a tel aviv hospital under Israel's compassion rule for terminal patients and both have survived. Looks like exciting work in their "snake oil". People seem to be scared of any new technology and will wait until they have a product on the market, missing the big run up (or down) during the development.

Recs

0
Member Avatar SuzaAdam (< 20) Submitted: 8/17/2012 3:35:08 PM : Outperform Start Price: $4.16 PSTI Score: -51.03

Superior technology

Recs

0
Member Avatar txboy70 (< 20) Submitted: 8/6/2012 10:28:36 PM : Outperform Start Price: $3.78 PSTI Score: -43.71

biotech has not been as tied to broad market ups and downs.
It is tied to the performance of it's product. PSTI has a product
which has MANY uses,not a one trick poney. It is patented and
is readily repeatable. delivery is simple. the drug stores well in
the typical medical office.

Recs

0
Member Avatar Ronsevet (< 20) Submitted: 3/29/2012 3:34:28 AM : Outperform Start Price: $2.21 PSTI Score: +25.49

A very well oriented stem company, with technological aspirations well in the realm of reality, extended their bioreactor capabilities just now,two phase two trials to be released in the near future with nice track record behind them.

Recs

0
Member Avatar Zippany (< 20) Submitted: 4/4/2011 12:10:46 PM : Outperform Start Price: $2.73 PSTI Score: -11.51

Cell therapeutics derived from placenta. Proprietary bioreactor. Based in Israel.

Recs

0
Member Avatar dgoldmeier (40.90) Submitted: 3/4/2011 4:30:52 PM : Outperform Start Price: $2.33 PSTI Score: +9.54

needs time and money to develop, but if it is sucsessfull will become a billion + powerhouse.

Recs

0
Member Avatar NanoORBust (< 20) Submitted: 2/3/2011 5:41:51 PM : Outperform Start Price: $2.98 PSTI Score: -27.62

Seems to be following that pattern set by Mesoblast only with a much smaller market cap.

Results 1 - 11 of 11

Featured Broker Partners


Advertisement